Dr. Xun-long Shi obtained his Ph.D. from Fudan University in 2008, Shanghai. He worked in Department of Microbiology and Biochemical Pharmacy for novel antiviral mechanism researches. He chaired two projects of Shanghai and national natural science foundation, participated in five National Science and Technology Major Projects for Drug Discovery. To now, he has published more than 20 papers and 22 application and granted patens. As the director of the center of anti-inflammation and anti-virus drug screening, his major scientific interests focused on exploring the interaction of drug materials, hosts and viruses. He found the modulation of the host response might be a novel anti-viral research field.
Virus-host crosstalk pathway; Antiviral chemotherapy and immunotherapy; Host factor-based antiviral therapeutics; Pre-clinical evaluation of novel Anti-inflammation and anti-virus candidates
Education
2002.09-2008.07 Master and Ph.D., School of Pharmacy, Fudan University
1998.09-2002.07 Bachelor, School of Pharmacy, Fudan University
Professional Experiences
2014.12- Associate Professor, Department of Microbiological ＆ Biochemical Pharmacy, School of Pharmacy, Fudan University
2008.09-2014.12 Assistant professor, Department of Biosynthesis, School of Pharmacy, Fudan University
Teaching Activities
Courses taught: Pharmaceutical Microbiology, Biopharmaceutics, Biopharmaceutical technology, Biosynthetic medicinal chemistry, Virus versus human being
Grants & Projects
1. Design, Synthesis, Pharmacological Activity and Structure-activity Study of Novel Acyclic Nucleosides. Major program of NSFC-Henan joint Project, No. U1604283 (2017-2020). Subproject leader （Antiviral）.
2. Switching macrophages polarization against influenza virus infection via PI3K pathway. The project of Shanghai Natural Science Foundation, No. 17ZR1401700 (2017-2020), Project leader.
3. Metabolomics study of active melaleuca A induced macrophages polarization shift against influenza virus infection. The major project of Shanghai Municipal Commission of Health and Family Planning, No. 201704200 (2018-2020). Project leader.
4. Pharmacodynamics and Mechanism of QingReJieDu Chinese Traditional Medicines in Respiratory system virus infection. The major project of National Natural Science Foundation of China, no.81330089 (2014-2018). Major participant
5. rhTNT antibody interleukin 2 fusion protein for immunotherapy of malignant cancer. National Science and Technology Major Project for Drug Discovery of the Ministry of Science and Technology of China, No.2011ZX09102-001-27 (2011-2013). Vice project leader.
Memberships
Member of the fifth council of china medicinal biotech association (2014-2019)
Selected Publications（latest 5 yrs，<20 papers）
1. Hai Huang, Wei Zhou, Haiyan Zhu, Pei Zhou and Xunlong Shi, Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs, Toxicol Appl Pharmacol., 2017, 323: 36-43
2. Xunlong Shi, Wei Zhou, Hai Huang, Hongguang Zhu, Pei Zhou, Haiyan Zhu, Dianwen Ju. Inhibition of the inflammatory cytokine TNF-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice. Crit Care 2013, 17: R301
3. Xunlong Shi, Zhihui Shi, Hai Huang, Hongguang Zhu, Pei Zhou, Haiyan Zhu, Dianwen Ju. Ability of recombinant human catalase to suppress inflammation of the murine lung induced by influenza A. Inflammation 2013, 37(3): 809-17
4. Xunlong Shi, Zhihui Shi, Hai Huang, Hongguang Zhu, Haiyan Zhu, Dianwen Ju, Pei Zhou. PEGylated human catalase elicits potent therapeutic effects on H1N1 influenza-induced pneumonia in mice. Appl Microbiol Biotechnol. 2013, 97: 10025-33, DOI: 10.1007/s00253-013-4775-3
5. Xun-Long Shi1, Zhi-Hui Shi1, Mei-Qing Feng, Li Ye, Hai-Yan Zhu, Ji-Yang Li, Dian-Wen Ju, Pei Zhou. High expression of recombinant human catalase and its immunomodulatory effects on H1N1 influenza virus infection. Process Biochem 2013, 48: 588- 92
6. 6. Z Wang, X Shi1, Y Li, J Fan, X Zeng, Y Sun, S Wang, P Song, S Zhao, H Hu and D Ju，Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells。Cell Death Dis 2014, 5, e; doi:10.1038/cddis.2014.503
7. Xunlong Shi1, Jianjun Yang1, Haiyan Zhu, Li Ye, Meiqing Feng, Jiyang Li, Hai Huang, Qun Tao, Dan Ye, Lee-Hwei K Sun, Bill NC Sun, Cecily RY Sun, Guizhen Han, Yuanyuan Liu, Minghui Yao, Pei Zhou, Dianwen Ju. Pharmacokinetics and pharmacodynamics of recombinant human EPO-Fc fusion protein in vivo. Plos One 2013, DOI: 10.1371/journal.pone.0072673
8. Ziyu Wang1, Xunlong Shi1, Yubin Li, Xian Zeng, Jiajun Fan, Yun Sun, Zongshu Xian, Guoping Zhang, Shaofei Wang, Haifeng Hu, Dianwen Ju. Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells. Appl Microbiol Biotechnol. 2013, 98: 2485-2494
9. Wei Zhou, Xiaohui Liu, Pei Zhang, Pei Zhou and Xunlong Shi*, Effect Analysis of Mineral Salt Concentrations on Nosiheptide Production by Streptomyces actuosus Z-10 Using Response Surface Methodology. Molecules 2014, 19: 15507-15520
10. Wei Zhou, Xiaohui Liu, Li Ye, Meiqing Feng, Pei Zhou, Xunlong Shi*, The biotransformation of astragalosides by a novel acetyl esterase from Absidia corymbifera AS2. Process Biochemistry, 2014, 49: 1464-71
11. Weina Wang1, Xunlong Shi1, Yuan Yuan, Haiyan Zhu, Wei Zhou, Hai Huang, and Meiqing Feng. The inhibitory effect of apolipoprotein A-I on matrix metalloproteinase-2 expression in vivo and in vitro. Acta Biochim Biophys Sin 2013, 45: 194-202
Licensed Patents
1. A targeting hepatitis B core antigen chimeric therapeutic vaccine and usage. ZL 2012 1018 5406.2.
2. Microbial transformation of astragalosides to astragaloside IV by Absidia corymbifera AS2. ZL 2010 1 0615265.4
3. Biotransformation of ginsenoside Rb1 to ginsenoside Rd. ZL 2011 1 0207782.2
